{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:46:38Z","timestamp":1776419198007,"version":"3.51.2"},"reference-count":245,"publisher":"Bentham Science Publishers Ltd.","issue":"13","funder":[{"DOI":"10.13039\/501100004895","name":"Fundo Social Europeu (FSE), Portugal","doi-asserted-by":"publisher","award":["SFRH\/BPD\/122871\/2016"],"award-info":[{"award-number":["SFRH\/BPD\/122871\/2016"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT-Foundation for Science and Technology","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-030457"],"award-info":[{"award-number":["POCI-01-0145-FEDER-030457"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Programme (NORTE 2020), Under European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000051"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000051"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Programme (NORTE 2020), Under European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Drug repurposing is a strategy used to develop new treatments based on approved or in-vestigational drugs outside the scope of their original clinical indication. Since this approach bene-fits from the original toxicity data of the repurposed drugs, the drug-repurposing strategy is time-saving, and inexpensive. It has a higher success rate compared to traditional drug discovery. Several repurposing candidates have been identified in silico screening and in vitro methodologies. One of the best examples is non-steroidal anti-inflammatory drugs (NSAIDs). Tumor-promoting inflamma-tion is one of the hallmarks of cancer, revealing a connection between inflammatory processes and tumor progression and development. This explains why using NSAIDs in the context of neoplasia has become a topic of interest. Indeed, identifying NSAIDs with antitumor activity has become a promising strategy for finding novel cancer treatment opportunities. Indeed, several commercial anti-inflammatory drugs, including aspirin, ibuprofen, diclofenac, celecoxib, tepoxalin and cyclo- valone, naproxen, and indomethacin have presented antitumor activity, and some of them are al-ready in clinical trials for cancer treatment. However, the benefits and complications of using NSAIDs for cancer treatment must be carefully evaluated, particularly for cancer patients with no further therapeutic options available. This review article provides insight into the drug repurposing strategy and describes some of the well-known NSAIDs that have been investigated as repurposed drugs with potential anticancer activity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026623666230130150029","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T04:18:15Z","timestamp":1675138695000},"page":"1171-1195","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Repurposing some of the Well-known Non-steroid Anti-inflammatory\nDrugs (NSAIDs) for Cancer Treatment"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-4643","authenticated-orcid":true,"given":"Maria Helena","family":"Vasconcelos","sequence":"first","affiliation":[{"name":"i3S - Instituto de\nInvestiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal"},{"name":"Cancer\nDrug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Rua\nAlfredo Allen 208, Porto, 4200-135, Portugal"},{"name":"Department of Biological Sciences, FFUP - Faculty of Pharmacy,\nUniversity of Porto, Rua de Jorge Viterbo Ferreira 228, Porto, 4050-313, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-2143","authenticated-orcid":true,"given":"Andreia","family":"Palmeira","sequence":"first","affiliation":[{"name":"LQOF - Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of\nPharmacy, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR - Interdisciplinary Centre\nof Marine and Environmental Research, Terminal de Cruzeiros do Porto de Leix\u00f5es, Matosinhos, 4450-208, Portugal"}]},{"given":"Sofia Martins","family":"Sousa","sequence":"additional","affiliation":[{"name":"LQOF - Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of\nPharmacy, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"i3S - Instituto de\nInvestiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal"},{"name":"Cancer\nDrug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Rua\nAlfredo Allen 208, Porto, 4200-135, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-1917","authenticated-orcid":true,"given":"Cristina Pinto Ribeiro","family":"Xavier","sequence":"additional","affiliation":[{"name":"i3S - Instituto de\nInvestiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal"},{"name":"Cancer\nDrug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Rua\nAlfredo Allen 208, Porto, 4200-135, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"DiMasi J.A.","year":"2016","unstructured":"DiMasi J.A.; Grabowski H.G.; Hansen R.W.; Innovation in the pharmaceutical industry: New estimates of RandD costs. J Health Econ 2016,47,20-33","journal-title":"J Health Econ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"Hay M.","year":"2014","unstructured":"Hay M.; Thomas D.W.; Craighead J.L.; Economides C.; Rosenthal J.; Clinical development success rates for investigational drugs. Nat Biotechnol 2014,32(1),40-51","journal-title":"Nat Biotechnol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/17460441.2021.1912733","volume":"16","author":"Gil C.","year":"2021","unstructured":"Gil C.; Martinez A.; Is drug repurposing really the future of drug discovery or is new innovation truly the way forward? Expert Opin Drug Discov 2021,16(8),829-831","journal-title":"Expert Opin Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","volume":"72","author":"Jourdan J.P.","year":"2020","unstructured":"Jourdan J.P.; Bureau R.; Rochais C.; Dallemagne P.; Drug repositioning: A brief overview. J Phar Pharmacol 2020,72(9),1145-1151","journal-title":"J Phar Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"Langedijk J.","year":"2015","unstructured":"Langedijk J.; Mantel-Teeuwisse A.K.; Slijkerman D.S.; Schutjens M.H.D.B.; Drug repositioning and repurposing: Terminology and definitions in literature. Drug Discov Today 2015,20(8),1027-1034","journal-title":"Drug Discov Today"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/DDDT.S46289","volume":"7","author":"Allarakhia M.","year":"2013","unstructured":"Allarakhia M.; Open-source approaches for the repurposing of existing or failed candidate drugs: Learning from and applying the lessons across diseases. Drug Des Devel Ther 2013,7,753-766","journal-title":"Drug Des Devel Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41564-019-0357-1","volume":"4","author":"Farha M.A.","year":"2019","unstructured":"Farha M.A.; Brown E.D.; Drug repurposing for antimicrobial discovery. Nat Microbiol 2019,4(4),565-577","journal-title":"Nat Microbiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"Corsello S.M.","year":"2017","unstructured":"Corsello S.M.; Bittker J.A.; Liu Z.; Gould J.; McCarren P.; Hirschman J.E.; Johnston S.E.; Vrcic A.; Wong B.; Khan M.; Asiedu J.; Narayan R.; Mader C.C.; Subramanian A.; Golub T.R.; The drug repurposing hub: A next-generation drug library and information resource. Nat Med 2017,23(4),405-408","journal-title":"Nat Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/ph13060132","volume":"13","author":"Palmeira A.","year":"2020","unstructured":"Palmeira A.; Sousa E.; K\u00f6seler A.; Sabirli R.; G\u00f6ren T.; T\u00fcrk\u00e7\u00fcer \u0130.; Kurt \u00d6.; Pinto M.M.; Vasconcelos M.H.; Preliminary virtual screening studies to identify GRP78 inhibitors which may interfere with SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2020,13(6),132","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/ph14030280","volume":"14","author":"Rebelo R.","year":"2021","unstructured":"Rebelo R.; Pol\u00f3nia B.; Santos L.L.; Vasconcelos M.H.; Xavier C.P.R.; Drug repurposing opportunities in pancreatic ductal adenocarcinoma. Pharmaceuticals (Basel) 2021,14(3),280","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.3390\/ijms23073631","volume":"23","author":"Branco H.","year":"2022","unstructured":"Branco H.; Oliveira J.; Antunes C.; Santos L.L.; Vasconcelos M.H.; Xavier C.P.R.; Pirfenidone sensitizes NCI-H460 non-small cell lung cancer cells to paclitaxel and to a combination of paclitaxel with carboplatin. Int J Mol Sci 2022,23(7),3631","journal-title":"Int J Mol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1747-0285.2011.01089.x","volume":"78","author":"Palmeira A.","year":"2011","unstructured":"Palmeira A.; Rodrigues F.; Sousa E.; Pinto M.; Vasconcelos M.H.; Fernandes M.X.; New uses for old drugs: Pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des 2011,78(1),57-72","journal-title":"Chem Biol Drug Des"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/pharmaceutics12050410","volume":"12","author":"Moreira-Silva F.","year":"2020","unstructured":"Moreira-Silva F.; Camilo V.; Gaspar V.; Mano J.F.; Henrique R.; Jer\u00f3nimo C.; Repurposing old drugs into new epigenetic inhibitors: Promising candidates for cancer treatment? Pharmaceutics 2020,12(5),410","journal-title":"Pharmaceutics"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2019","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Escott K.J.; Hopper S.; Wells A.; Doig A.; Guilliams T.; Latimer J.; McNamee C.; Norris A.; Sanseau P.; Cavalla D.; Pirmohamed M.; Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.biopha.2018.11.127","volume":"110","author":"Gns HS","year":"2019","unstructured":"Gns HS; Gr S; Murahari M; Krishnamurthy M; An update on drug repurposing: Re-written saga of the drug's fate. Biomed Pharmacother 2019,110,700-716","journal-title":"Biomed Pharmacother"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.addr.2018.04.010","volume":"133","author":"Newman S.P.","year":"2018","unstructured":"Newman S.P.; Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. Adv Drug Deliv Rev 2018,133,5-18","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.drup.2020.100713","volume":"52","author":"Dini\u0107 J.","year":"2020","unstructured":"Dini\u0107 J.; Efferth T.; Garc\u00eda-Sosa A.T.; Grahovac J.; Padr\u00f3n J.M.; Pajeva I.; Rizzolio F.; Saponara S.; Spengler G.; Tsakovska I.; Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat 2020,52,100713","journal-title":"Drug Resist Updat"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"817663","DOI":"10.3389\/fmed.2021.817663","volume":"8","author":"Asker-Hagelberg C.","year":"2022","unstructured":"Asker-Hagelberg C.; Boran T.; Bouygues C.; Eskola S.M.; Helmle L.; Hern\u00e1ndez C.; Hou\u00fdez F.; Lee H.; Lingri D.D.; Louette L.; Meheus L.; Penninckx W.; Stepniewska B.; Repurposing of medicines in the eu: Launch of a pilot framework. Front Med 2022,8,817663","journal-title":"Front Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.14318","volume":"111","author":"Masuda T.","year":"2020","unstructured":"Masuda T.; Tsuruda Y.; Matsumoto Y.; Uchida H.; Nakayama K.I.; Mimori K.; Drug repositioning in cancer: The current situation in Japan. Cancer Sci 2020,111(4),1039-1046","journal-title":"Cancer Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"Xue H.","year":"2018","unstructured":"Xue H.; Li J.; Xie H.; Wang Y.; Review of drug repositioning approaches and resources. Int J Biol Sci 2018,14(10),1232-1244","journal-title":"Int J Biol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"790952","DOI":"10.3389\/fphar.2021.790952","volume":"12","author":"Pantziarka P.","year":"2021","unstructured":"Pantziarka P.; Vandeborne L.; Bouche G.; A database of drug repurposing clinical trials in oncology. Front Pharmacol 2021,12,790952","journal-title":"Front Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.18632\/oncoscience.173","volume":"2","author":"Kato S.","year":"2015","unstructured":"Kato S.; Moulder S.L.; Ueno N.T.; Wheler J.J.; Meric-Bernstam F.; Kurzrock R.; Janku F.; Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2015,2(6),576-580","journal-title":"Oncoscience"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/B978-0-12-802808-7.00012-5","author":"Naveja J.J.","year":"2016","unstructured":"Naveja J.J.; Due\u00f1as-Gonz\u00e1lez A.; Medina-Franco J.L.; Drug repurposing for epigenetic targets guided by computational methods. Epi-Informatics 2016,327-357","journal-title":"Epi-Informatics"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3897\/pharmacia.69.e72548","volume":"69","author":"Ayyar P.","year":"2022","unstructured":"Ayyar P.; Subramanian U.; Repurposing - second life for drugs. Pharmacia 2022,69(1),51-59","journal-title":"Pharmacia"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ddstr.2011.06.007","volume":"8","author":"Witkowski T.X.","year":"2011","unstructured":"Witkowski T.X.; Intellectual property and other legal aspects of drug repurposing. Drug Discov Today Ther Strateg 2011,8(3-4),139-143","journal-title":"Drug Discov Today Ther Strateg"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4324\/9781315373669-1","author":"Cavalla D.","year":"2017","unstructured":"Cavalla D.; Scientific and commercial value of drug repurposing. Drug Repositioning 2017,3-22","journal-title":"Drug Repositioning"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrd.2018.92","volume":"18","author":"Breckenridge A.","year":"2019","unstructured":"Breckenridge A.; Jacob R.; Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 2019,18(1),1-2","journal-title":"Nat Rev Drug Discov"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"170098","DOI":"10.1183\/16000617.0098-2017","volume":"27","author":"Boyer A","year":"2018","unstructured":"Boyer A; Pasquier E; Tomasini P; Ciccolini J; Greillier L; Andre N; Drug repurposing in malignant pleural mesothelioma: A breath of fresh air? Eur Respir Rev 2018,27(147),170098","journal-title":"Eur Respir Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cancers8070066","volume":"8","author":"Ahmed K.","year":"2016","unstructured":"Ahmed K.; Shaw H.; Koval A.; Katanaev V.; A second wnt for old drugs: Drug repositioning against wnt-dependent cancers. Cancers 2016,8(7),66","journal-title":"Cancers"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd4051","volume":"12","author":"Plenge R.M.","year":"2013","unstructured":"Plenge R.M.; Scolnick E.M.; Altshuler D.; Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013,12(8),581-594","journal-title":"Nat Rev Drug Discov"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.drudis.2012.08.005","volume":"18","author":"Liu Z.","year":"2013","unstructured":"Liu Z.; Fang H.; Reagan K.; Xu X.; Mendrick D.L.; Slikker W.; Tong W.; In Silico Drug Repositioning \u2013 What We Need To Know. Drug Discov Today 2013,18(3-4),110-115","journal-title":"Drug Discov Today"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","volume":"19","author":"Jin G.","year":"2014","unstructured":"Jin G.; Wong S.T.C.; Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014,19(5),637-644","journal-title":"Drug Discov Today"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.91941","author":"Dhir N.","year":"2020","unstructured":"Dhir N.; Jain A.; Mahendru D.; Prakash A.; Medhi B.; Drug repurposing and orphan disease therapeutics. 2020"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1101\/197434","author":"Pantziarka P.","year":"2017","unstructured":"Pantziarka P.; Sukhatme V.; Meheus L.; Sukhatme V.; Bouche G.; Repurposing non-cancer drugs in oncology - how many drugs are out there? bioRxiv 2017","journal-title":"bioRxiv"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","volume":"5","author":"Zhang Z.","year":"2020","unstructured":"Zhang Z.; Zhou L.; Xie N.; Nice E.C.; Zhang T.; Cui Y.; Huang C.; Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020,5(1),113","journal-title":"Signal Transduct Target Ther"},{"key":"ref=37","first-page":"488","volume":"18","author":"Yang H.T.","year":"2017","unstructured":"Yang H.T.; Ju J.H.; Wong Y.T.; Shmulevich I.; Chiang J.H.; Literature-based discovery of new candidates for drug repurposing. Brief Bioinform 2017,18(3),488-497","journal-title":"Brief Bioinform"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/9781608058648115010004","author":"Bellera C.L.","year":"2015","unstructured":"Bellera C.L.; Di Ianni M.E.; Sbaraglini M.L.; Castro E.A.; Bruno-Blanch L.E.; Talevi A.; Knowledge-based drug repurposing: A rational approach towards the identification of novel medical applications of known drugs. Frontiers in Computational Chemistry 2015,44-81","journal-title":"Frontiers in Computational Chemistry"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","volume":"1871","author":"Nowak-Sliwinska P.","year":"2019","unstructured":"Nowak-Sliwinska P.; Scapozza L.; Ruiz i Altaba A.; Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019,1871(2),434-454","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/PPO.0000000000000360","volume":"25","author":"Orecchioni S.","year":"2019","unstructured":"Orecchioni S.; Roma S.; Raimondi S.; Gandini S.; Bertolini F.; Identifying drug repurposing opportunities in oncology. Cancer J 2019,25(2),82-87","journal-title":"Cancer J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","volume":"12","author":"Bertolini F.","year":"2015","unstructured":"Bertolini F.; Sukhatme V.P.; Bouche G.; Drug repurposing in oncology\u2014patient and health systems opportunities. Nat Rev Clin Oncol 2015,12(12),732-742","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/wsbm.1337","volume":"8","author":"Hodos R.A.","year":"2016","unstructured":"Hodos R.A.; Kidd B.A.; Shameer K.; Readhead B.P.; Dudley J.T.; in silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016,8(3),186-210","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00298","volume":"8","author":"March-Vila E","year":"2017","unstructured":"March-Vila E; Pinzi L; Sturm N; Tinivella A; Engkvist O; Chen H; On the integration of in silico drug design methods for drug repurposing. Front Pharmacol 2017,8(298),1-7","journal-title":"Front Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.semcancer.2020.01.010","volume":"68","author":"Adasme M.F.","year":"2020","unstructured":"Adasme M.F.; Parisi D.; Sveshnikova A.; Schroeder M.; Structure-based drug repositioning: Potential and limits. Semin Cancer Biol 2020,68,192-198","journal-title":"Semin Cancer Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/978-1-60761-839-3_19","volume":"672","author":"Vidal D.","year":"2011","unstructured":"Vidal D.; Garcia-Serna R.; Mestres J.; Ligand-based approaches to in silico pharmacology. Methods Mol Biol 2011,672,489-502","journal-title":"Methods Mol Biol"},{"key":"ref=46","author":"Pinto MMM.","year":"2011","unstructured":"Pinto MMM.; Manual de trabalhos laboratoriais de qu\u00edmica org\u00e2nica e farmac\u00eautica. ISBN: 978-972-757-750-7.2011"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1087057114563024","volume":"20","author":"Wilkinson G.F.","year":"2015","unstructured":"Wilkinson G.F.; Pritchard K.; In vitro screening for drug repositioning. SLAS Discov 2015,20(2),167-179","journal-title":"SLAS Discov"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2011.255","volume":"26","author":"Deshpande A.","year":"2012","unstructured":"Deshpande A.; Reddy M.M.; Schade G.O.M.; Ray A.; Chowdary T.K.; Griffin J.D.; Sattler M.; Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012,26(4),708-715","journal-title":"Leukemia"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"Corsello S.M.","year":"2020","unstructured":"Corsello S.M.; Nagari R.T.; Spangler R.D.; Rossen J.; Kocak M.; Bryan J.G.; Humeidi R.; Peck D.; Wu X.; Tang A.A.; Wang V.M.; Bender S.A.; Lemire E.; Narayan R.; Montgomery P.; Ben-David U.; Garvie C.W.; Chen Y.; Rees M.G.; Lyons N.J.; McFarland J.M.; Wong B.T.; Wang L.; Dumont N.; O\u2019Hearn P.J.; Stefan E.; Doench J.G.; Harrington C.N.; Greulich H.; Meyerson M.; Vazquez F.; Subramanian A.; Roth J.A.; Bittker J.A.; Boehm J.S.; Mader C.C.; Tsherniak A.; Golub T.R.; Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer 2020,1(2),235-248","journal-title":"Nat Cancer"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"Sleire L.","year":"2017","unstructured":"Sleire L.; F\u00f8rde H.E.; Netland I.A.; Leiss L.; Skeie B.S.; Enger P.\u00d8.; Drug repurposing in cancer. Pharmacol Res 2017,124,74-91","journal-title":"Pharmacol Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3332\/ecancer.2018.886","volume":"12","author":"Pantziarka P.","year":"2018","unstructured":"Pantziarka P.; Verbaanderd C.; Sukhatme V.; Capistrano R.; Crispino S.; Gyawali B.; Rooman I.; Van Nuffel A.M.T.; Meheus L.; Sukhatme V.P.; Bouche G.; ReDO_DB: The repurposing drugs in oncology database. Ecancermedicalscience 2018,12,886","journal-title":"Ecancermedicalscience"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3332\/ecancer.2014.485","volume":"8","author":"Pantziarka P.","year":"2014","unstructured":"Pantziarka P.; Bouche G.; Meheus L.; Sukhatme V.; Sukhatme V.P.; Vikas P.; The repurposing drugs in oncology (ReDO) project. Ecancermedicalscience 2014,8,442","journal-title":"Ecancermedicalscience"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","volume":"8","author":"Oprea T.I.","year":"2011","unstructured":"Oprea T.I.; Bauman J.E.; Bologa C.G.; Buranda T.; Chigaev A.; Edwards B.S.; Jarvik J.W.; Gresham H.D.; Haynes M.K.; Hjelle B.; Hromas R.; Hudson L.; Mackenzie D.A.; Muller C.Y.; Reed J.C.; Simons P.C.; Smagley Y.; Strouse J.; Surviladze Z.; Thompson T.; Ursu O.; Waller A.; Wandinger-Ness A.; Winter S.S.; Wu Y.; Young S.M.; Larson R.S.; Willman C.; Sklar L.A.; Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011,8(3-4),61-69","journal-title":"Drug Discov Today Ther Strateg"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","volume":"21","author":"W\u00fcrth R.","year":"2016","unstructured":"W\u00fcrth R.; Thellung S.; Bajetto A.; Mazzanti M.; Florio T.; Barbieri F.; Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds. Drug Discov Today 2016,21(1),190-199","journal-title":"Drug Discov Today"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.semcancer.2020.01.008","volume":"68","author":"Pantziarka P.","year":"2020","unstructured":"Pantziarka P.; Verbaanderd C.; Huys I.; Bouche G.; Meheus L.; Repurposing drugs in oncology: From candidate selection to clini-cal adoption. Semin Cancer Biol 2020,68,186-191","journal-title":"Semin Cancer Biol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"Hanahan D.","year":"2022","unstructured":"Hanahan D.; Hallmarks of cancer: New dimensions. Cancer Discov 2022,12(1),31-46","journal-title":"Cancer Discov"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.rpor.2020.04.004","volume":"25","author":"Piotrowski I.","year":"2020","unstructured":"Piotrowski I.; Kulcenty K.; Suchorska W.; Interplay between inflammation and cancer. Rep Pract Oncol Radiother 2020,25(3),422-427","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"Bindu S.","year":"2020","unstructured":"Bindu S.; Mazumder S.; Bandyopadhyay U.; Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 2020,180,114147","journal-title":"Biochem Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","volume":"104","author":"Vane J.R.","year":"1998","unstructured":"Vane J.R.; Botting R.M.; Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998,104(3),2S-8S","journal-title":"Am J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s000110050284","volume":"47","author":"Vane J.R.","year":"1998","unstructured":"Vane J.R.; Botting R.M.; Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998,47(S2),78-87","journal-title":"Inflamm Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"81s","DOI":"10.18433\/j3t886","volume":"11","author":"Rao P.","year":"2008","unstructured":"Rao P.; Knaus E.; Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (cox) inhibition and beyond. J Pharm Pharm Sci 2008,11,81s-110s","journal-title":"J Pharm Pharm Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.3390\/ijms22126637","volume":"22","year":"2021","unstructured":"Kadu\u0161evi\u010dius, E. Novel applications of NSAIDs: Insight and future perspectives in cardiovascular, neurodegenerative, diabetes and cancer disease therapy. Int J Mol Sci 2021,22(12),6637","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0950-3579(88)80019-0","volume":"2","author":"Day R.O.","year":"1988","unstructured":"Day R.O.; Graham G.G.; Williams K.M.; Pharmacokinetics of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988,2(2),363-393","journal-title":"Baillieres Clin Rheumatol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/187152312803476255","volume":"11","author":"Bacchi S.","year":"2012","unstructured":"Bacchi S.; Palumbo P.; Sponta A.; Coppolino M.F.; Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review. Antiinflamm Antiallergy Agents Med Chem 2012,11(1),52-64","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev.med.57.121304.131253","volume":"58","author":"Cha Y.I.","year":"2007","unstructured":"Cha Y.I.; DuBois R.N.; NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med 2007,58(1),239-252","journal-title":"Annu Rev Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/ijms23031432","volume":"23","author":"Kolawole O.R.","year":"2022","unstructured":"Kolawole O.R.; Kashfi K.; NSAIDs and cancer resolution: New paradigms beyond cyclooxygenase. Int J Mol Sci 2022,23(3),1432","journal-title":"Int J Mol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.bcp.2005.05.004","volume":"70","author":"Kashfi K.","year":"2005","unstructured":"Kashfi K.; Rigas B.; Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 2005,70(7),969-986","journal-title":"Biochem Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3390\/ijms21072605","volume":"21","author":"Zappavigna S.","year":"2020","unstructured":"Zappavigna S.; Cossu A.M.; Grimaldi A.; Bocchetti M.; Ferraro G.A.; Nicoletti G.F.; Filosa R.; Caraglia M.; Anti-inflammatory drugs as anticancer agents. Int J Mol Sci 2020,21(7),2605","journal-title":"Int J Mol Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"16380","DOI":"10.1021\/acs.jmedchem.1c01460","volume":"64","author":"Ramos-Inza S.","year":"2021","unstructured":"Ramos-Inza S.; Ruberte A.C.; Sanmart\u00edn C.; Sharma A.K.; Plano D.; NSAIDs: Old acquaintance in the pipeline for cancer treatment and prevention-structural modulation, mechanisms of action, and bright future. J Med Chem 2021,64(22),16380-16421","journal-title":"J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"105155","DOI":"10.1016\/j.tiv.2021.105155","volume":"74","author":"Okamoto K.","year":"2021","unstructured":"Okamoto K.; Saito Y.; Narumi K.; Furugen A.; Iseki K.; Kobayashi M.; Anticancer effects of non-steroidal anti-inflammatory drugs against cancer cells and cancer stem cells. Toxicol In Vitro 2021,74,105155","journal-title":"Toxicol In Vitro"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.2147\/CMAR.S253345","volume":"12","author":"Fu X.","year":"2020","unstructured":"Fu X.; Tan T.; Liu P.; Regulation of autophagy by non-steroidal anti-inflammatory drugs in cancer. Cancer Manag Res 2020,12,4595-4604","journal-title":"Cancer Manag Res"},{"key":"ref=72","first-page":"20","volume":"21","author":"Sankaranarayanan R.","year":"2020","unstructured":"Sankaranarayanan R.; Valiveti C.K.; Dachineni R.; Kumar D.R.; Lick T.; Bhat G.J.; Aspirin metabolites 2,3-DHBA and 2,5-DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention. Mol Med Rep 2020,21(1),20-34","journal-title":"Mol Med Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3892\/ijo.2017.4167","volume":"51","author":"Dachineni R.","year":"2017","unstructured":"Dachineni R.; Kumar D.R.; Callegari E.; Kesharwani S.S.; Sankaranarayanan R.; Seefeldt T.; Tummala H.; Bhat G.J.; Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin\u2019s chemopreventive effects against colorectal cancer. Int J Oncol 2017,51(6),1661-1673","journal-title":"Int J Oncol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1158\/1541-7786.MCR-15-0360","volume":"14","author":"Dachineni R.","year":"2016","unstructured":"Dachineni R.; Ai G.; Kumar D.R.; Sadhu S.S.; Tummala H.; Bhat G.J.; Cyclin A2 and CDK2 as novel targets of aspirin and salicylic acid: A potential role in cancer prevention. Mol Cancer Res 2016,14(3),241-252","journal-title":"Mol Cancer Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-17-0242","volume":"23","author":"Dai X.","year":"2017","unstructured":"Dai X.; Yan J.; Fu X.; Pan Q.; Sun D.; Xu Y.; Wang J.; Nie L.; Tong L.; Shen A.; Zheng M.; Huang M.; Tan M.; Liu H.; Huang X.; Ding J.; Geng M.; Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res 2017,23(20),6267-6278","journal-title":"Clin Cancer Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e1791","DOI":"10.7717\/peerj.1791","volume":"4","author":"Dai S.X.","year":"2016","unstructured":"Dai S.X.; Li W.X.; Li G.H.; Huang J.F.; Proteome-wide prediction of targets for aspirin: New insight into the molecular mechanism of aspirin. PeerJ 2016,4,e1791","journal-title":"PeerJ"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s10637-018-0568-y","volume":"36","author":"Amaral M.E.A.","year":"2018","unstructured":"Amaral M.E.A.; Nery L.R.; Leite C.E.; de Azevedo Junior, W.F.; Campos M.M.; Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs 2018,36(5),782-796","journal-title":"Invest New Drugs"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"7, 274","DOI":"10.22146\/ijc.21196","volume":"15","author":"Istyastono E.P.","year":"2015","unstructured":"Istyastono E.P.; Riswanto F.D.O.; Yuliani S.H.; Computer-aided drug repurposing: A cyclooxygenase-2 inhibitor celecoxib as a ligand for estrogen receptor alpha. Indonesian J Chem 2015,15(3),7, 274-280","journal-title":"Indonesian J Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jtbi.2019.01.020","volume":"465","author":"Pandey S.K.","year":"2019","unstructured":"Pandey S.K.; Yadav S.; Goel Y.; Temre M.K.; Singh V.K.; Singh S.M.; Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics. J Theor Biol 2019,465,117-125","journal-title":"J Theor Biol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/onc.2017.328","volume":"37","author":"Nagaraj A.B.","year":"2018","unstructured":"Nagaraj A.B.; Wang Q.Q.; Joseph P.; Zheng C.; Chen Y.; Kovalenko O.; Singh S.; Armstrong A.; Resnick K.; Zanotti K.; Waggoner S.; Xu R.; DiFeo A.; Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 2018,37(3),403-414","journal-title":"Oncogene"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.008","volume":"457","author":"Lin C.C.","year":"2019","unstructured":"Lin C.C.; Suen K.M.; Stainthorp A.; Wieteska L.; Biggs G.S.; Leit\u00e3o A.; Montanari C.A.; Ladbury J.E.; Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling. Cancer Lett 2019,457,86-97","journal-title":"Cancer Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/1940-6207.CAPR-13-0288","volume":"7","author":"Kim M.S.","year":"2014","unstructured":"Kim M.S.; Kim J.E.; Lim D.Y.; Huang Z.; Chen H.; Langfald A.; Lubet R.A.; Grubbs C.J.; Dong Z.; Bode A.M.; Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K. Cancer Prev Res 2014,7(2),236-245","journal-title":"Cancer Prev Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2014.12.007","volume":"166","author":"Dilwali S.","year":"2015","unstructured":"Dilwali S.; Kao S.Y.; Fujita T.; Landegger L.D.; Stankovic K.M.; Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl Res 2015,166(1),1-11","journal-title":"Transl Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13058-018-1074-z","volume":"20","author":"Bhardwaj A.","year":"2018","unstructured":"Bhardwaj A.; Singh H.; Trinidad C.M.; Albarracin C.T.; Hunt K.K.; Bedrosian I.; The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res 2018,20(1),150","journal-title":"Breast Cancer Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","volume":"113","author":"Montinari M.R.","year":"2019","unstructured":"Montinari M.R.; Minelli S.; De Caterina R.; The first 3500 years of aspirin history from its roots \u2013 A concise summary. Vascul Pharmacol 2019,113,1-8","journal-title":"Vascul Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","volume":"110","author":"Vane J.R.","year":"2003","unstructured":"Vane J.R.; Botting R.M.; The mechanism of action of aspirin. Thromb Res 2003,110(5-6),255-258","journal-title":"Thromb Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"Awtry E.H.","year":"2000","unstructured":"Awtry E.H.; Loscalzo J.; Aspirin. Circulation 2000,101(10),1206-1218","journal-title":"Circulation"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/1389450121999201013152931","volume":"22","author":"Zheng L.","year":"2020","unstructured":"Zheng L.; Lv W.; Zhou Y.; Lin X.; Yao J.; Progress on the mechanism for aspirin\u2019s anti-tumor effects. Curr Drug Targets 2020,22(1),105-111","journal-title":"Curr Drug Targets"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4664651","volume":"2022","author":"Xiao X.","year":"2022","unstructured":"Xiao X.; Zeng S.; Li Y.; Li L.; Zhang J.; Aspirin suppressed pdl1 expression through suppressing kat5 and subsequently inhibited pd-1 and pd-l1 signaling to attenuate oc development. J Oncol 2022,2022,1-13","journal-title":"J Oncol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neo.2021.12.004","volume":"24","author":"Rodriguez Lanzi C.","year":"2022","unstructured":"Rodriguez Lanzi C.; Wei R.; Luo D.; Mackenzie G.G.; Phosphoaspirin (mdc-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and kpc mice by targeting EGFR: Enhanced efficacy in combination with irinotecan. Neoplasia 2022,24(2),133-144","journal-title":"Neoplasia"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"685954","DOI":"10.3389\/fcell.2021.685954","volume":"9","author":"Liang S.","year":"2021","unstructured":"Liang S.; Zhou X.; Cai D.; Rodrigues-Lima F.; Chi J.; Wang L.; Network pharmacology and experimental validation reveal the effects of chidamide combined with aspirin on acute myeloid leukemia-myelodysplastic syndrome cells through pi3k\/akt pathway. Front Cell Dev Biol 2021,9,685954","journal-title":"Front Cell Dev Biol"},{"key":"ref=92","unstructured":"A trial of aspirin on recurrence and survival in colon cancer patients (ASPIRIN). Clinicaltrials.govAvailable from:"},{"key":"ref=93","unstructured":"Using aspirin to improve immunological features of ovarian tumors. Clinicaltrials.govAvailable from:"},{"key":"ref=94","unstructured":"Study of aspirin in patients with vestibular schwannoma. Clinicaltrials.govAvailable from:"},{"key":"ref=95","unstructured":"Adjuvant low dose aspirin in colorectal cancer (ALASCCA). Clinicaltrials.govAvailable from:"},{"key":"ref=96","unstructured":"Regorafenib in combination with metronomic chemotherapies, and low-dose aspirin in metastatic colorectal cancer (REPROGRAM-01). Clinicaltrials.govAvailable from:"},{"key":"ref=97","unstructured":"A Phase III double-blind placebo-controlled randomised trial of aspirin on recurrence and survival in colon cancer patients. Clinicaltrials.govAvailable from:"},{"key":"ref=98","unstructured":"Trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE-4). Clinicaltrials.govAvailable from:"},{"key":"ref=99","unstructured":"Aspirin and rintatolimod with or without interferon-alpha 2b in treating patients with prostate cancer before surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=100","unstructured":"Clinical study of antiviral and aspirin treatment in liver cancer after radical surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=101","unstructured":"Pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Clinicaltrials.govAvailable from:"},{"key":"ref=102","unstructured":"Adjuvant aspirin treatment for colon cancer patients. Clinicaltrials.govAvailable from:"},{"key":"ref=103","unstructured":"Aspirin for dukes c and high risk dukes b colorectal cancers (ASCOLT). Clinicaltrials.govAvailable from:"},{"key":"ref=104","unstructured":"RACIN in patients with advanced til-negative solid tumors (RACIN). Clinicaltrials.govAvailable from:"},{"key":"ref=105","unstructured":"Anti-programmed cell death-1 ligand 1 (apdl-1) antibody atezolizumab, bevacizumab and acetylsalicylic acid in recurrent platinum resistant ovarian cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=106","unstructured":"Prostaglandin inhibition and immune checkpoint blockade in melanoma. Clinicaltrials.govAvailable from:"},{"key":"ref=107","unstructured":"Dexamethasone, aspirin, and diethylstilbestrol in treating patients with locally advanced or metastatic prostate cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=108","unstructured":"The effect of aspirin on angiogenesis proteins in women on tamoxifen therapy. Clinicaltrials.govAvailable from:"},{"key":"ref=109","unstructured":"Study of pembrolizumab, radiation and immune modulatory cocktail in cervical\/uterine cancer (PRIMMO). Clinicaltrials.govAvailable from:"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2741\/1429","volume":"9","author":"Chu A.J.","year":"2004","unstructured":"Chu A.J.; Chou T.H.; Chen B.D.; Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front Biosci 2004,9(1-3),2697-2713","journal-title":"Front Biosci"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2174\/1389450119666180803121737","volume":"20","author":"To\u0142oczko-Iwaniuk N.","year":"2019","unstructured":"To\u0142oczko-Iwaniuk N.; Dziemia\u0144czyk-Pakie\u0142a D.; Nowaszewska B.K.; Celi\u0144ska-Janowicz K.; Miltyk W.; Celecoxib in cancer therapy and prevention \u2013 review. Curr Drug Targets 2019,20(3),302-315","journal-title":"Curr Drug Targets"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.pan.2018.02.006","volume":"18","author":"Zuo C.","year":"2018","unstructured":"Zuo C.; Hong Y.; Qiu X.; Yang D.; Liu N.; Sheng X.; Zhou K.; Tang B.; Xiong S.; Ma M.; Liu Z.; Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3\/NF-kB and L1CAM activities. Pancreatology 2018,18(3),328-333","journal-title":"Pancreatology"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"115254","DOI":"10.18632\/oncotarget.23250","volume":"8","author":"Huang C.","year":"2017","unstructured":"Huang C.; Chen Y.; Liu H.; Yang J.; Song X.; Zhao J.; He N.; Zhou C.J.; Wang Y.; Huang C.; Dong Q.; Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Oncotarget 2017,8(70),115254-115269","journal-title":"Oncotarget"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cas.13106","volume":"108","author":"Egashira I.","year":"2017","unstructured":"Egashira I.; Takahashi-Yanaga F.; Nishida R.; Arioka M.; Igawa K.; Tomooka K.; Nakatsu Y.; Tsuzuki T.; Nakabeppu Y.; Kitazono T.; Sasaguri T.; Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt\/\u03b2-catenin signaling pathway. Cancer Sci 2017,108(1),108-115","journal-title":"Cancer Sci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"e0223760","DOI":"10.1371\/journal.pone.0223760","volume":"14","author":"Zhang P.","year":"2019","unstructured":"Zhang P.; He D.; Song E.; Jiang M.; Song Y.; Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt\/mTOR signaling pathway and COX-2 expression. PLoS One 2019,14(10),e0223760","journal-title":"PLoS One"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","volume":"332","author":"Jendrossek V.","year":"2013","unstructured":"Jendrossek V.; Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2013,332(2),313-324","journal-title":"Cancer Lett"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.biopha.2012.01.004","volume":"66","author":"Vaish V.","year":"2012","unstructured":"Vaish V.; Sanyal S.N.; Role of sulindac and celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring pi3-k\/pten\/akt pathway to the canonical wnt\/\u03b2-catenin signaling. Biomed Pharmacother 2012,66(5),354-367","journal-title":"Biomed Pharmacother"},{"key":"ref=118","unstructured":"Chidamide + celecoxib in advanced metastatic colorectal cancer (CCmCC). Clinicaltrials.govAvailable from:"},{"key":"ref=119","unstructured":"Celecoxib with chemotherapy in localized, muscle-invasive bladder cancer (BLAST). Clinicaltrials.govAvailable from:"},{"key":"ref=120","unstructured":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=121","unstructured":"Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=122","unstructured":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer (GCRP). Clinicaltrials.govAvailable from:"},{"key":"ref=123","unstructured":"Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma (CELEBRIDO). Clinicaltrials.govAvailable from:"},{"key":"ref=124","unstructured":"Sirolimus in combination with metronomic chemotherapy in children with recurrent and\/or refractory solid and cns tumors (AflacST1502). Clinicaltrials.govAvailable from:"},{"key":"ref=125","unstructured":"Toripalimab with or without celecoxib as neoadjuvant therapy in resectable dMMR\/MSI-H colorectal cancer (PICC). Clinicaltrials.govAvailable from:"},{"key":"ref=126","unstructured":"Nivolumab, Ipilimumab and COX2-inhibition in early stage colon cancer: an unbiased approach for signals of sensitivity (NICHE). Clinicaltrials.govAvailable from:"},{"key":"ref=127","unstructured":"Chemokine modulation therapy and standard chemotherapy before surgery for the treatment of early stage triple negative breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=128","unstructured":"Systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy (stampede). Clinicaltrials.govAvailable from:"},{"key":"ref=129","unstructured":"Serial measurements of molecular and architectural responses to therapy (SMMART) PRIME Trial). Clinicaltrials.govAvailable from:"},{"key":"ref=130","unstructured":"Metronomic treatment in children and adolescents with recurrent or progressive high risk neuroblastoma (METRO-NB2012). Clinicaltrials.govAvailable from:"},{"key":"ref=131","unstructured":"Antiangiogenic therapy for children with recurrent medulloblastoma, ependymoma and ATRT (MEMMAT). Clinicaltrials.govAvailable from:"},{"key":"ref=132","unstructured":"Cyclophosphamide with or without celecoxib in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=133","unstructured":"Window of Opportunity Study Targeting the Inflammatory Milieu. Clinicaltrials.govAvailable from:"},{"key":"ref=134","unstructured":"N2012-01: Phase 1 study of difluoromethylornithine (dfmo) and celecoxib with cyclophosphamide\/topotecan (DFMO). Clinicaltrials.govAvailable from:"},{"key":"ref=135","unstructured":"Efficacy and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE). Clinicaltrials.govAvailable from:"},{"key":"ref=136","unstructured":"Gemcitabine and celecoxib in treating patients with metastatic pancreatic cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=137","unstructured":"Celecoxib and docetaxel in treating patients with non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=138","unstructured":"Randomized controlled phase ii trial of preoperative celecoxib treatment in breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=139","unstructured":"Celecoxib and docetaxel in treating patients with advanced non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=140","unstructured":"Celecoxib and radiation therapy in treating patients with locally advanced non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=141","unstructured":"Celecoxib and trastuzumab in treating women with metastatic breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=142","unstructured":"Paclitaxel and carboplatin with or without celecoxib before surgery in treating patients with stage iiia nonsmall cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=143","unstructured":"Exemestane with celecoxib as neoadjuvant treatment in postmenopausal women with stage ii, iii, and iv breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=144","unstructured":"CPT-11\/Cisplatin and celecoxib with radiation therapy for patients with unresectable non-small cell lung cancer (NSCLC). Clinicaltrials.govAvailable from:"},{"key":"ref=145","unstructured":"Atorvastatin calcium and celecoxib in treating patients with rising psa levels after local therapy for prostate cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=146","unstructured":"Trial of celecoxib with preoperative chemoradiation for locally advanced rectal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=147","unstructured":"Celecoxib in treating patients with stage iiib or stage iv non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=148","unstructured":"Patent Cetuximab and celecoxib for metastatic colorectal cancer or colorectal cancer that cannot be removed by surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=149","unstructured":"Cisplatin, CPT-11 and celecoxib with radiation therapy and surgery for operable esophageal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=150","unstructured":"Irinotecan, cisplatin, and radiation therapy with or without celecoxib in treating patients with stage ii, stage iii, or stage iv esophageal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=151","unstructured":"Celecoxib and erlotinib in treating patients with stage IIIB or stage iv non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=152","unstructured":"Celecoxib for the treatment of non-muscle invasive bladder cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=153","unstructured":"Gefitinib and celecoxib in treating patients with refractory non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=154","unstructured":"Study on the neoadjuvant use of chemotherapy and celecoxib therapy in patients with invasive breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=155","unstructured":"Exemestane + celecoxib vs exemestane + placebo in metastatic breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=156","unstructured":"Gemcitabine, cisplatin, and celecoxib treatment of metastatic pancreatic cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=157","unstructured":"Combination chemotherapy and celecoxib in treating patients with advanced non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=158","unstructured":"Celecoxib, fluorouracil, and radiation therapy in treating patients with stage ii or stage iii rectal cancer that can be removed by surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=159","unstructured":"Study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients (carbo-cox2). Clinicaltrials.govAvailable from:"},{"key":"ref=160","unstructured":"Celecoxib, capecitabine, and irinotecan in treating patients with recurrent or metastatic colorectal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=161","unstructured":"Celecoxib and erlotinib in treating former smokers with stage iiib or stage iv non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=162","unstructured":"Celecoxib combined with fluorouracil and leucovorin in treating patients with resected stage iii adenocarcinoma (cancer) of the colon. Clinicaltrials.govAvailable from:"},{"key":"ref=163","unstructured":"Combination chemotherapy treatments in patients with metastatic colorectal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=164","unstructured":"Radiation therapy plus celecoxib, fluorouracil, and cisplatin in patients with locally advanced cervical cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=165","unstructured":"Celebrex with preoperative chemoradiation - rectal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=166","unstructured":"Celecoxib and recombinant interferon alfa-2b in metastatic kidney cancer who have undergone surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=167","unstructured":"Combination chemotherapy with or without celecoxib in treating patients with metastatic colorectal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=168","unstructured":"Erlotinib and celecoxib in treating patients with stage iiib or stage iv recurrent non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=169","unstructured":"Celecoxib in treating patients with progressive metastatic differentiated thyroid cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=170","unstructured":"Irinotecan and celecoxib in treating patients with unresectable or metastatic colorectal cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=171","unstructured":"Celecoxib in treating postmenopausal women who are undergoing surgery for invasive breast cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=172","unstructured":"Celecoxib, paclitaxel, and carboplatin in treating patients with cancer of the esophagus. Clinicaltrials.govAvailable from:"},{"key":"ref=173","unstructured":"Carboplatin and gemcitabine combined with celecoxib and\/or zileuton in treating patients with advanced nonsmall cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=174","unstructured":"Erlotinib hydrochloride with or without celecoxib in treating patients with stage iiib-iv non-small cell lung cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=175","unstructured":"Bortezomib and celecoxib in treating patients with advanced solid tumors. Clinicaltrials.govAvailable from:"},{"key":"ref=176","unstructured":"Erlotinib, celecoxib and reirradiation for recurrent head and neck cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=177","unstructured":"Celecoxib, recombinant interferon alfa-2b, and rintatolimod in treating patients with colorectal cancer metastatic to the liver. Clinicaltrials.govAvailable from:"},{"key":"ref=178","unstructured":"Cyclophosphamide and celecoxib in treating patients with advanced cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=179","unstructured":"Etoposide and celecoxib in patients with advanced cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=180","unstructured":"Epirubicin and celecoxib in treating patients with hepatocellular carcinoma. Clinicaltrials.govAvailable from:"},{"key":"ref=181","unstructured":"Etoposide, cyclophosphamide, thalidomide, celecoxib, and fenofibrate in relapsed or progressive cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=182","unstructured":"Celebrex - Cervix: Celecoxib in the treatment of patients with locally advanced carcinoma of the cervix. Clinicaltrials.govAvailable from:"},{"key":"ref=183","unstructured":"Thalidomide, celecoxib, and combination chemotherapy in treating patients with relapsed or refractory malignant glioma. Clinicaltrials.govAvailable from:"},{"key":"ref=184","unstructured":"Temozolomide, thalidomide, and celecoxib following radiation therapy in treating patients with newly diagnosed glioblastoma multiforme. Clinicaltrials.govAvailable from:"},{"key":"ref=185","unstructured":"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients. Clinicaltrials.govAvailable from:"},{"key":"ref=186","unstructured":"Temozolomide alone or in combination with thalidomide and\/or isotretinoin and\/or celecoxib in treating patients who have undergone radiation therapy for glioblastoma multiforme. Clinicaltrials.govAvailable from:"},{"key":"ref=187","unstructured":"Vinblastine, celecoxib, and combination chemotherapy in treating patients with newly-diagnosed metastatic ewing's sarcoma family of tumors. Clinicaltrials.govAvailable from:"},{"key":"ref=188","unstructured":"ANGIOCOMB antiangiogenic therapy for pediatric patients with diffuse brain stem and thalamic tumors. Clinicaltrials.govAvailable from:"},{"key":"ref=189","unstructured":"Celecoxib and radiation therapy in treating patients with stage ii or stage iii soft tissue sarcoma of the arm, hand, leg, or foot that has been removed by surgery. Clinicaltrials.govAvailable from:"},{"key":"ref=190","unstructured":"A study of nasopharyngeal carcinoma (NPC) treated with celecoxib and ZD1839. Clinicaltrials.govAvailable from:"},{"key":"ref=191","unstructured":"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (cusp9v3 treatment protocol) for recurrent glioblastoma. Clinicaltrials.govAvailable from:"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1749-8546-3-11","volume":"3","author":"Itokawa H.","year":"2008","unstructured":"Itokawa H.; Shi Q.; Akiyama T.; Morris-Natschke S.L.; Lee K.H.; Recent advances in the investigation of curcuminoids. Chin Med 2008,3(1),11","journal-title":"Chin Med"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"13282","DOI":"10.3390\/molecules190913282","volume":"19","author":"Lamperti M.","year":"2014","unstructured":"Lamperti M.; Maspero A.; T\u00f8nnesen H.; Bondani M.; Nardo L.; Elucidation of the relationships between H-bonding patterns and excited state dynamics in cyclovalone. Molecules 2014,19(9),13282-13304","journal-title":"Molecules"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11094-007-0087-1","volume":"41","author":"Simonyan M.A.","year":"2007","unstructured":"Simonyan M.A.; Dib K.; Pashkov A.N.; Simonyan A.V.; Myachina O.V.; Ostrovskii O.V.; Synthesis and antiradical and antioxidant activity of cycvalon and its analogs. Pharm Chem J 2007,41(8),403-406","journal-title":"Pharm Chem J"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.13005\/ojc\/330607","volume":"33","author":"Hayun H.","year":"2017","unstructured":"Hayun H.; Jatmika C.; Maras Maswati E.; Salim S.; Kurniawan R.; Greffiana Chandra Adam Arditya Fajriawan E.; Desthahrina Nareswara A.; Synthesis and free radical-scavenging activities of di-mannich bases of cyclovalone derivatives. Orient J Chem 2017,33(6),2742-2757","journal-title":"Orient J Chem"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/ijo.12.5.1127","volume":"12","author":"Markaverich B.M.","year":"1998","unstructured":"Markaverich B.M.; Alejandro M.A.; Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation. Int J Oncol 1998,12(5),1127-1135","journal-title":"Int J Oncol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3332\/ecancer.2016.610","volume":"10","author":"Pantziarka P.","year":"2016","unstructured":"Pantziarka P.; Sukhatme V.; Bouche G.; Melhuis L.; Sukhatme V.P.; Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience 2016,10,610","journal-title":"Ecancermedicalscience"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40122-018-0100-2","volume":"7","author":"Atzeni F.","year":"2018","unstructured":"Atzeni F.; Masala I.F.; Sarzi-Puttini P.; A review of chronic musculoskeletal pain: central and peripheral effects of diclofenac. Pain Ther 2018,7(2),163-177","journal-title":"Pain Ther"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.3390\/ijms22105067","volume":"22","author":"Galisteo A.","year":"2021","unstructured":"Galisteo A.; Jannus F.; Garc\u00eda-Garc\u00eda A.; Aheget H.; Rojas S.; Lupia\u00f1ez J.A.; Rodr\u00edguez-Di\u00e9guez A.; Reyes-Zurita F.J.; Qu\u00edlez del Moral J.F.; Diclofenac N-Derivatives as Therapeutic Agents with Anti-Inflammatory and Anti-Cancer Effect. Int J Mol Sci 2021,22(10),5067","journal-title":"Int J Mol Sci"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"e0140613","DOI":"10.1371\/journal.pone.0140613","volume":"10","author":"Leidgens V.","year":"2015","unstructured":"Leidgens V.; Seliger C.; Jachnik B.; Welz T.; Leukel P.; Vollmann-Zwerenz A.; Bogdahn U.; Kreutz M.; Grauer O.M.; Hau P.; Ibuprofen and diclofenac restrict migration and proliferation of human glioma cells by distinct molecular mechanisms. PLoS One 2015,10(10),e0140613","journal-title":"PLoS One"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3390\/cancers12092683","volume":"12","author":"Poku R.A.","year":"2020","unstructured":"Poku R.A.; Jones K.J.; Van Baren M.; Alan J.K.; Amissah F.; Diclofenac enhances docosahexaenoic acid-induced apoptosis in vitro in lung cancer cells. Cancers 2020,12(9),2683","journal-title":"Cancers"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3390\/cancers11101453","volume":"11","author":"Duval A.P.","year":"2019","unstructured":"Duval A.P.; Troquier L.; Demartines ; Dormond ; Dormond O.; Diclofenac potentiates sorafenib-based treatments of hepatocellular carcinoma by enhancing oxidative stress. Cancers 2019,11(10),1453","journal-title":"Cancers"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.3390\/ijms19092586","volume":"19","author":"Gerthofer V.","year":"2018","unstructured":"Gerthofer V.; Kreutz M.; Renner K.; Jachnik B.; Dettmer K.; Oefner P.; Riemenschneider M.; Proescholdt M.; Vollmann-Zwerenz A.; Hau P.; Seliger C.; Combined modulation of tumor metabolism by metformin and diclofenac in glioma. Int J Mol Sci 2018,19(9),2586","journal-title":"Int J Mol Sci"},{"key":"ref=204","unstructured":"Topical vitamin D3, Diclofenac or a combination of both to treat basal cell carcinoma. Clinicaltrials.govAvailable from:"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/03639045.2017.1391838","volume":"44","author":"Irvine J.","year":"2018","unstructured":"Irvine J.; Afrose A.; Islam N.; Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm 2018,44(2),173-183","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=206","first-page":"82","volume":"71","author":"Barbagallo M.","year":"2019","unstructured":"Barbagallo M.; Sacerdote P.; Ibuprofen in the treatment of children\u2019s inflammatory pain: a clinical and pharmacological overview. Minerva Pediatr 2019,71(1),82-99","journal-title":"Minerva Pediatr"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G","volume":"42","author":"Gupta S.","year":"2000","unstructured":"Gupta S.; Srivastava M.; Ahmad N.; Bostwick D.G.; Mukhtar H.; Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000,42(1),73-78","journal-title":"Prostate"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C","volume":"89","author":"Yoshimura R.","year":"2000","unstructured":"Yoshimura R.; Sano H.; Masuda C.; Kawamura M.; Tsubouchi Y.; Chargui J.; Yoshimura N.; Hla T.; Wada S.; Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000,89(3),589-596","journal-title":"Cancer"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41416-020-0906-7","volume":"123","author":"Shen W.","year":"2020","unstructured":"Shen W.; Zhang X.; Du R.; Gao W.; Wang J.; Bao Y.; Yang W.; Luo N.; Li J.; Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner. Br J Cancer 2020,123(5),730-741","journal-title":"Br J Cancer"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1007\/s13277-014-2952-3","volume":"36","author":"Akrami H.","year":"2015","unstructured":"Akrami H.; Aminzadeh S.; Fallahi H.; Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol 2015,36(5),3237-3243","journal-title":"Tumour Biol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00280-002-0485-8","volume":"50","author":"Andrews J.","year":"2002","unstructured":"Andrews J.; Djakiew D.; Krygier S.; Andrews P.; Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2002,50(4),277-284","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1038\/cddis.2013.550","volume":"5","author":"Endo H.","year":"2014","unstructured":"Endo H.; Yano M.; Okumura Y.; Kido H.; Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis 2014,5(1),e1027","journal-title":"Cell Death Dis"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/cbin.10959","volume":"42","author":"Akrami H.","year":"2018","unstructured":"Akrami H.; Moradi B.; Borzabadi Farahani D.; Mehdizadeh K.; Ibuprofen reduces cell proliferation through inhibiting Wnt\/\u03b2 catenin signaling pathway in gastric cancer stem cells. Cell Biol Int 2018,42(8),949-958","journal-title":"Cell Biol Int"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/03639045.2020.1776319","volume":"46","author":"Yurtda\u015f-K\u0131r\u0131ml\u0131o\u011flu G.","year":"2020","unstructured":"Yurtda\u015f-K\u0131r\u0131ml\u0131o\u011flu G.; G\u00f6rg\u00fcl\u00fc \u015e.; Berkman M.S.; Novel approaches to cancer therapy with ibuprofen-loaded Eudragit \u00ae RS 100 and\/or octadecylamine-modified PLGA nanoparticles by assessment of their effects on apoptosis. Drug Dev Ind Pharm 2020,46(7),1133-1149","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"226","DOI":"10.25258\/ijddt.9.2.18","volume":"9","author":"Ali AA","year":"2019","unstructured":"Ali AA; Al-Khafaji T; Al-Obaidi Z; Synthesis of novel ibuprofen-tranexamic acid codrug: Estimation of the clinical activity against hct116 colorectal carcinoma cell line and the determination of toxicity profile against mdck normal kidney cell line. Int J Drug Del Tech 2019,9,226-235","journal-title":"Int J Drug Del Tech"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40425-018-0406-y","volume":"6","author":"Pennock N.D.","year":"2018","unstructured":"Pennock N.D.; Martinson H.A.; Guo Q.; Betts C.B.; Jindal S.; Tsujikawa T.; Coussens L.M.; Borges V.F.; Schedin P.; Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 2018,6(1),98","journal-title":"J Immunother Cancer"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.prnil.2019.09.003","volume":"7","author":"Arisan E.D.","year":"2019","unstructured":"Arisan E.D.; Akar R.O.; Rencuzogullari O.; Obakan Yerlikaya P.; Coker Gurkan A.; Ak\u0131n B.; Dener E.; Kayhan E.; Palavan Unsal N.; The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells. Prostate Int 2019,7(4),156-165","journal-title":"Prostate Int"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1039\/C5CP00272A","volume":"17","author":"Husain M.A.","year":"2015","unstructured":"Husain M.A.; Sarwar T.; Rehman S.U.; Ishqi H.M.; Tabish M.; Ibuprofen causes photocleavage through ROS generation and intercalates with DNA: a combined biophysical and molecular docking approach. Phys Chem Chem Phys 2015,17(21),13837-13850","journal-title":"Phys Chem Chem Phys"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/j.pain.0000000000002032","volume":"162","author":"Summ O.","year":"2021","unstructured":"Summ O.; Andreou A.P.; Akerman S.; Holland P.R.; Hoffmann J.; Goadsby P.J.; Differential actions of indomethacin: Clinical relevance in headache. Pain 2021,162(2),591-599","journal-title":"Pain"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/head.12769","volume":"56","author":"Lucas S.","year":"2016","unstructured":"Lucas S.; The pharmacology of indomethacin. Headache 2016,56(2),436-446","journal-title":"Headache"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/14787210.2022.1990756","volume":"20","author":"Shekhar N.","year":"2022","unstructured":"Shekhar N.; Kaur H.; Sarma P.; Prakash A.; Medhi B.; Indomethacin: An exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19. Expert Rev Anti Infect Ther 2022,20(3),383-390","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"8238","DOI":"10.1074\/jbc.RA118.004415","volume":"294","author":"Mazumder S.","year":"2019","unstructured":"Mazumder S.; De R.; Debsharma S.; Bindu S.; Maity P.; Sarkar S.; Saha S.J.; Siddiqui A.A.; Banerjee C.; Nag S.; Saha D.; Pramanik S.; Mitra K.; Bandyopadhyay U.; Indomethacin impairs mitochondrial dynamics by activating the PKC\u03b6\u2013p38\u2013DRP1 pathway and inducing apoptosis in gastric cancer and normal mucosal cells. J Biol Chem 2019,294(20),8238-8258","journal-title":"J Biol Chem"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"e22433","DOI":"10.1002\/jbt.22433","volume":"34","author":"Seetha A.","year":"2020","unstructured":"Seetha A.; Devaraj H.; Sudhandiran G.; Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol 2020,34(2),e22433","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=224","unstructured":"Enzalutamide and indomethacin in treating patients with recurrent or metastatic hormone-resistant prostate cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=225","unstructured":"IRX-2 regimen in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. Clinicaltrials.govAvailable from:"},{"key":"ref=226","unstructured":"Pre-operative irx-2 in early stage breast cancer (ESBC). Clinicaltrials.govAvailable from:"},{"key":"ref=227","unstructured":"IRX-2 regimen in patients with newly diagnosed stage ii, iii, or iva squamous cell carcinoma of the oral cavity (INSPIRE). Clinicaltrials.govAvailable from:"},{"key":"ref=228","unstructured":"A phase ii neoadjuvant study of apalutamide, abiraterone acetate, prednisone, degarelix and indomethacin in men with localized prostate cancer pre-prostatectomy Clinicaltrials.govAvailable from:"},{"key":"ref=229","unstructured":"Preoperative non-steroidal anti-inflammatory drugs(NSAID) to colorectal cancer patients. Clinicaltrials.govAvailable from:"},{"key":"ref=230","unstructured":"A phase 2 clinical trial of the safety and effects of irx-2 in treating patients with operable head and neck cancer. Clinicaltrials.govAvailable from:"},{"key":"ref=231","unstructured":"Indomethacin plus biological therapy in treating patients with advanced melanoma. Clinicaltrials.govAvailable from:"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2174\/1389557520666200505124922","volume":"20","author":"Han M.\u0130","year":"2020","unstructured":"Han M.\u0130; K\u00fc\u00e7\u00fckg\u00fczel \u015e.G.; Anticancer and antimicrobial activities of naproxen and naproxen derivatives. Mini Rev Med Chem 2020,20(13),1300-1310","journal-title":"Mini Rev Med Chem"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.3390\/molecules26164792","volume":"26","author":"Ha M.W.","year":"2021","unstructured":"Ha M.W.; Paek S.M.; Recent advances in the synthesis of ibuprofen and naproxen. Molecules 2021,26(16),4792","journal-title":"Molecules"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40256-016-0200-5","volume":"17","author":"Angiolillo D.J.","year":"2017","unstructured":"Angiolillo D.J.; Weisman S.M.; Clinical pharmacology and cardiovascular safety of naproxen. Am J Cardiovasc Drugs 2017,17(2),97-107","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","volume":"17","author":"Schjerning A.M.","year":"2020","unstructured":"Schjerning A.M.; McGettigan P.; Gislason G.; Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol 2020,17(9),574-584","journal-title":"Nat Rev Cardiol"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"112024","DOI":"10.1016\/j.msec.2021.112024","volume":"124","author":"Espinosa-Cano E.","year":"2021","unstructured":"Espinosa-Cano E.; Huerta-Madro\u00f1al M.; C\u00e1mara-S\u00e1nchez P.; Seras-Franzoso J.; Schwartz S.; Abasolo I.; San Rom\u00e1n J.; Aguilar M.R.; Hyaluronic acid (HA)-coated naproxen-nanoparticles selectively target breast cancer stem cells through COX-independent pathways. Mater Sci Eng C 2021,124,112024","journal-title":"Mater Sci Eng C"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.neo.2021.05.010","volume":"23","author":"Kumar G.","year":"2021","unstructured":"Kumar G.; Madka V.; Singh A.; Farooqui M.; Stratton N.; Lightfoot S.; Mohammed A.; Rao C.V.; Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice. Neoplasia 2021,23(6),574-583","journal-title":"Neoplasia"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-319-33889-7_2","author":"Rius B.","year":"2016","unstructured":"Rius B.; Cl\u00e0ria J.;  Principles, mechanisms of action, and future prospects of anti-inflammatory drugs NSAIDs and Aspirin: Recent Advances and Implications for Clinical Management 2016,17-34","journal-title":"Principles, mechanisms of action, and future prospects of anti-inflammatory drugs NSAIDs and Aspirin: Recent Advances and Implications for Clinical Management"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejps.2018.06.003","volume":"121","author":"P J.J.","year":"2018","unstructured":"P J.J.; Manju S.L.; Ethiraj K.R.; Elias G.; Safer anti-inflammatory therapy through dual COX-2\/5-LOX inhibitors: A structure-based approach. Eur J Pharm Sci 2018,121,356-381","journal-title":"Eur J Pharm Sci"},{"key":"ref=240","first-page":"205","volume":"9","author":"Sunilchandra U.","year":"2020","unstructured":"Sunilchandra U.; Ravikumar C.; Rashmi R.; Analgesics in animal pain management. Pharma Innovation J 2020,9(4),205-209","journal-title":"Pharma Innovation J"},{"key":"ref=241","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7897\/2277-4572.081119","volume":"8","author":"Dewangan R.","year":"2019","unstructured":"Dewangan R.; Tiwari S.; Physiology of pain and its management in veterinary patients. Pharma Innov 2019,8,11-68","journal-title":"Pharma Innov"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0006-2952(01)00747-X","volume":"62","author":"Fiorucci S.","year":"2001","unstructured":"Fiorucci S.; Meli R.; Bucci M.; Cirino G.; Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? 1 1Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclooxygenase; LT, leukotriene; 5-LOX, 5-lipoxygenase; PG, prostaglandin; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsuphonyl)-phenyl-2(5H)-furanone; and DFP, diisopropyl fluorophosphate. Biochem Pharmacol 2001,62(11),1433-1438","journal-title":"Biochem Pharmacol"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1476-5829.2010.00240.x","volume":"9","author":"Sottnik J.L.","year":"2011","unstructured":"Sottnik J.L.; Hansen R.J.; Gustafson D.L.; Dow S.W.; Thamm D.H.; Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft. Vet Comp Oncol 2011,9(2),118-130","journal-title":"Vet Comp Oncol"},{"key":"ref=244","first-page":"3847","volume":"10","author":"Lu X.","year":"2018","unstructured":"Lu X.; Huang L.; Zhang W.; Ning X.; Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice. Am J Transl Res 2018,10(11),3847-3856","journal-title":"Am J Transl Res"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"101181","DOI":"10.1016\/j.tranon.2021.101181","volume":"14","author":"McQuerry J.A.","year":"2021","unstructured":"McQuerry J.A.; Chen J.; Chang J.T.; Bild A.H.; Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1. Transl Oncol 2021,14(10),101181","journal-title":"Transl Oncol"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230130150029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213265\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230130150029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:17:27Z","timestamp":1693570647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213265\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":245,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026623666230130150029","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}